Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications

被引:0
|
作者
Steingrimsdottir, H [1 ]
Gruber, A
Björkholm, M
Svensson, A
Hansson, M
机构
[1] Karolinska Hosp, Dept Med, Div Hematol, SE-17176 Stockholm, Sweden
[2] Karolinska Inst, Stockholm, Sweden
[3] Karolinska Hosp, Dept Clin Immunol & Transfus Med, SE-17176 Stockholm, Sweden
关键词
autologous stem cell transplantation; immune reconstitution; hematopoietic reconstitution; infectious complication; lymphocyte subset recovery;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives. Autologous peripheral stem cell transplantation (APSCT) is increasingly used for various hematologic malignancies and sol; id tumors. The objective of this study was to analyze the immune reconstitution after APSCT and see ii there was any correlation with diagnosis, age, type of high-dose therapy, CD34(+) selection of the autograft and double vs single APSCT. Design and Methods. Lymphocyte subset recovery was studied in 46 consecutive patients with hematologic malignancies and breast cancer, who underwent APSCT. Eleven patients with multiple myeloma received tandem autografts. Thirty-one patients were given total body irradiation (TBI) as part of the high-dose treatment. Eighteen patients received a CD34(+) selected graft. The percentage and absolute numbers of lymphocyte populations, T-cells (CD2(+), CD3(+)), B-cells (CD19(+)), NK cells (CD56(+) CD3(-) and CD16(+)CD3(-)) and T-cell subpopulations [CD4(+), CD8(+), CD4(+)CD45RA(+), CD4(+) CD45RO(+), CD4(+)DR(+), CD8(+) CD45RO(+), CD8(+)DR(+)), were monitored with Row cytometry during the first year after APSCT. Results. The total B-cell (CD19(+)) and T-cell (CD3(+)) counts were reconstituted to normal levels 2-4 months after APSCT. All patients had a low CD4/CD8 ratio during the observation period, related to both a low number of CD4(+) cells and elevated numbers of CD8(+) cells. The low number of CD4(+) cells was due to a persistently low level of naive CD4(+)CD45RA(+) cells. A high proportion of the CD8(+) cells displayed a phenotype compatible with activated T-cells (CD8(+)DR(+)) up to 10 months after autografting. The number of NK cells (CD56(+)3(-) or CD16(+)3(-)) reached normal values within one month post-transplant. No single variable, such as diagnoses, age, TBI as part of the high-idose treatment, tandem autografting or CD34(+) selection of the graft, influenced the immune or hematopoietic reconstitution and no correlation with documented infectious complications was found. Interpretation and Conclusions. Despite heterogeneity of diseases, age, initial treatment and high-dose regimens, lymphocyte subset analysis did not reveal any differences in hematopoietic or immune reconstitution. AII patients had a low CD4(+)/CD8(+) ratio during at least the first year post-transplant, caused by a persistent increase of CD8(+) lymphocytes and a constant reduction of CD4(+) lymphocytes, making the patients susceptible to infections for a prolonged period of time post-transplant. (C)2000, Ferrata Storti Foundation.
引用
收藏
页码:832 / 838
页数:7
相关论文
共 50 条
  • [1] Late infectious complications after high-dose therapy and autologous blood stem cell transplantation
    Metzner, B
    Grüneisl, R
    Gebauer, W
    Reschke, D
    Ost, E
    Müller, TH
    Reichert, D
    Rosien, B
    del Valle, F
    Zirpel, I
    Kohse, KP
    Schunter, F
    Illiger, HJ
    [J]. MEDIZINISCHE KLINIK, 2002, 97 (11) : 650 - 658
  • [2] Infectious complications after high-dose therapy with autologous peripheral blood stem cell transplantation
    Sezer, O
    Eucker, J
    Fuss, H
    Bauhuis, C
    Kobert, U
    Heinzel, W
    Späth-Schwalbe, E
    Arnold, R
    Possinger, K
    Schultze, W
    [J]. HIGH-DOSE THERAPY AND TRANSPLANTATION OF HAEMATOPOIETIC STEM CELLS, 2000, : 90 - 93
  • [3] Infectious complications after high-dose chemotherapy and autologous stem cell transplantation.
    Reich, G
    Mapara, MY
    Reichardt, P
    Dörken, B
    Maschmeyer, G
    [J]. BLOOD, 1998, 92 (10) : 337B - 337B
  • [4] Immune reconstitution after autologous hematopoietic stem cell transplantation
    Porrata, LF
    Litzow, MR
    Markovic, SN
    [J]. MAYO CLINIC PROCEEDINGS, 2001, 76 (04) : 407 - 412
  • [5] High-dose immune suppression and autologous hematopoietic stem cell transplantation in refractory Crohn disease
    Burt, RK
    Traynor, A
    Oyama, Y
    Craig, R
    [J]. BLOOD, 2003, 101 (05) : 2064 - 2066
  • [6] Infectious complications after high-dose therapy and autologous stem cell transplantation: comparison of patients with acute leukaemia and lymphoma
    Mensah, P
    Hawrylecka, D
    Piatkowska-Jakubas, B
    Wegrzyn, J
    Krawczyk, J
    Skop, A
    Skotnicki, AB
    [J]. BONE MARROW TRANSPLANTATION, 2004, 33 : S320 - S321
  • [7] Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation
    Guillaume, T
    Rubinstein, DB
    Symann, M
    [J]. BLOOD, 1998, 92 (05) : 1471 - 1490
  • [8] Early infectious complications after high-dose-therapy and autologous blood stem cell transplantation
    Metzner, B
    Dirks, R
    Gebauer, W
    Reschke, D
    Müller, TH
    Ost, E
    Reichert, D
    Rosien, B
    del Valle, F
    Zirpel, I
    Hellkamp, J
    Kohse, KP
    Schunter, F
    Illiger, HJ
    [J]. ONKOLOGIE, 1999, 22 (06): : 491 - 496
  • [9] Immune reconstitution after high-dose chemotherapy (HDCT) followed by autologous peripheral stem cell transplantation (PBSCT).
    Reimer, P
    Kunzmann, V
    Weissinger, F
    Wilhelm, M
    [J]. BLOOD, 2000, 96 (11) : 402A - 403A
  • [10] Infectious complication in 314 patients after high-dose therapy and autologous hematopoietic stem cell transplantation: Risk factors analysis and outcome
    Gil, L.
    Styczynski, J.
    Komarnicki, M.
    [J]. INFECTION, 2007, 35 (06) : 421 - 427